Xgeva success in Trial "147" for prevention of bone metastases in Prostate Cancer

Amgen reports results of its study "147", which not only confirmed that its 120mg dosage form of denosumab, known as Xgeva, improved median bone metastasis-free survival by 4.2 months in men with castrate-resistant prostate cancer (CRPC) versus placebo � the first time a bone-targeted drug has delayed the spread of prostate cancer to the bones � but new data showed the drug also significantly delayed the time to first bone metastasis and the time to symptomatic,or painful, bone metastasis.The study "147 " data was unexpectedly favorable, with Xgeva patients having a median bone metastasis-free survival of 29.5 months, compared with 25.2 months for those on placebo � a risk reduction of 15%.